Inside Neuralink’s Human Trials: Speech AI, Digital Art, and a Growing Global Network

But the capability goes beyond generic text-to-speech. Neuralink’s team is actively working to restore Kenneth’s ability to communicate using his own voice, utilizing AI voice cloning from recordings made before ALS affected his speech . This detail distinguishes the project from simpler speech prosthetics. A company update confirmed they are “giving a patient named Kenneth his voice back” and that “it will sound like him” . CEO Elon Musk publicly shared video evidence of the milestone, calling it a restoration of speech for someone who had lost it entirely .

The technical performance supporting this work is significant. In the PRIME study, one patient sustained a communication rate of 40 words per minute over a two-month evaluation period using neural signals alone, a benchmark independently verified . While not yet matching the pace of natural conversation, it represents a functional speed for text-based communication.

The U.S. Food and Drug Administration granted Neuralink’s speech restoration technology Breakthrough Device Designation, a status reserved for technologies that offer a substantial improvement over existing options for life-threatening or irreversibly debilitating conditions . The designation is designed to expedite development and regulatory review.

The VOICE study, listed publicly on ClinicalTrials.gov under ID NCT07224256, is actively recruiting individuals with severe speech impairments resulting from ALS, stroke, spinal cord injury, and other conditions .

Art Created with Thought: The Story of Participant P9

In May 2026, Neuralink highlighted a different kind of breakthrough: the creative use of its motor-control implant. The company introduced participant P9, known as Crews, the ninth person and the first woman to receive a Neuralink implant. She sustained a C4/C5 spinal cord injury in a 2005 accident, resulting in quadriplegia .

After 20 years of paralysis, Crews is now producing digital art using only her neural signals . The Telepathy implant lets her move a cursor, write her name, and create intricate drawings through thought . Neuralink described the art as a way she “visually conveys her story through abstract art” .

The development expands the narrative around brain-computer interfaces beyond functional control of devices into realms of personal expression and identity. The technology here is the same Telepathy system that all 21 participants are using to operate computers, phones, and, in some cases, robotic limbs .

Trial Scale, Safety, and What’s Next

The 21 participants are spread across the PRIME and VOICE trials, with international sites now active in Canada and the United Kingdom . The FDA has approved a 15-participant expansion for the PRIME study, signaling regulatory comfort with the safety data collected so far . Across all enrolled participants, no serious device-related adverse events have been reported to date .

Elon Musk announced a next-generation implant with triple the channel count compared to the current N1 device, with human testing expected to begin later in the year . The company has set a public target of making 2026 the first year of large-scale production, though the path from experimental trials to a broadly available medical product remains lengthy and subject to further regulatory review .

Neuralink’s patient registry is now open worldwide for people interested in learning about eligibility for both the motor control and speech restoration trials .